Seattle Genetics Achieves Milestone Under Agreement With Genentech

Seattle Genetics, Inc. announced that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with Genentech, triggering an undisclosed payment to Seattle Genetics. The milestone is based on Genentech's continued progress in preclinical development with an ADC utilizing Seattle Genetics' technology.

Yahoo News (http://biz.yahoo.com/bw/050315/155390_1.html)